Total Payments
$75,300
2024 Payments
$52,392
Companies
65
Transactions
917
Medicare Patients
2,876
Medicare Billing
$412,157
Payment Breakdown by Category
Research$55,694 (74.0%)
Food & Beverage$17,122 (22.7%)
Travel$1,289 (1.7%)
Consulting$1,024 (1.4%)
Education$171.34 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55,694 | 6 | 74.0% |
| Food and Beverage | $17,122 | 890 | 22.7% |
| Travel and Lodging | $1,289 | 3 | 1.7% |
| Consulting Fee | $1,024 | 1 | 1.4% |
| Education | $171.34 | 17 | 0.2% |
Payments by Type
Research
$55,694
6 transactions
General
$19,606
911 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $55,694 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,063 | 72 | $0 (2024) |
| Novo Nordisk Inc | $1,570 | 100 | $0 (2024) |
| Amarin Pharma Inc. | $1,354 | 53 | $0 (2023) |
| AstraZeneca AB | $1,340 | 6 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,148 | 69 | $0 (2024) |
| Gilead Sciences, Inc. | $1,083 | 45 | $0 (2024) |
| Lilly USA, LLC | $889.31 | 52 | $0 (2024) |
| Amgen Inc. | $721.67 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $650.10 | 48 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52,392 | 83 | Eli Lilly and Company ($50,969) |
| 2023 | $4,288 | 103 | Eli Lilly and Company ($2,691) |
| 2022 | $4,528 | 129 | Eli Lilly and Company ($2,034) |
| 2021 | $2,615 | 139 | AstraZeneca Pharmaceuticals LP ($284.92) |
| 2020 | $1,731 | 100 | AstraZeneca Pharmaceuticals LP ($351.10) |
| 2019 | $3,009 | 111 | AstraZeneca Pharmaceuticals LP ($1,287) |
| 2018 | $2,409 | 113 | AstraZeneca Pharmaceuticals LP ($392.08) |
| 2017 | $4,327 | 139 | AstraZeneca AB ($1,340) |
All Payment Transactions
917 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.80 | General |
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Gastroenterology | ||||||
| 11/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Cardio-renal | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.80 | General |
| 11/05/2024 | Kowa Pharmaceuticals America, Inc. | ZORYVE (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: DERMATOLOGY | ||||||
| 10/28/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/26/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Biological | ||||||
| 10/24/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Diabetes Care | ||||||
| 10/21/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Gastroenterology | ||||||
| 10/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: DIABETES | ||||||
| 10/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Cardio-renal | ||||||
| 10/01/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 09/30/2024 | Azurity Pharmaceuticals, Inc. | EDARBI (Drug) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.25 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $46,318.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,316.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,335.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.52 | General |
| 09/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Diabetes | ||||||
| 09/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $46,318 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $4,759 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $3,369 | 2 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $1,248 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 920 | 8,428 | $421,026 | $139,109 |
| 2022 | 19 | 670 | 3,912 | $214,894 | $89,801 |
| 2021 | 16 | 637 | 3,354 | $222,746 | $105,098 |
| 2020 | 20 | 649 | 3,208 | $176,638 | $78,149 |
Total Patients
2,876
Total Services
18,902
Medicare Billing
$412,157
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 421 | $79,990 | $36,471 | 45.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 69 | 231 | $87,015 | $27,296 | 31.4% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 32 | 1,960 | $41,160 | $22,397 | 54.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 183 | $21,045 | $12,020 | 57.1% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 41 | 3,024 | $30,240 | $8,744 | 28.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 33 | 172 | $17,200 | $6,797 | 39.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 49 | 49 | $11,270 | $6,223 | 55.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 65 | $9,425 | $3,222 | 34.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 42 | 106 | $10,500 | $2,292 | 21.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 12 | 66 | $4,290 | $1,905 | 44.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 73 | 228 | $8,664 | $1,858 | 21.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 12 | 66 | $4,290 | $1,480 | 34.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 120 | $4,800 | $1,433 | 29.8% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 12 | 66 | $2,640 | $1,015 | 38.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 112 | $8,064 | $989.43 | 12.3% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 33 | 33 | $1,815 | $836.88 | 46.1% |
| J3415 | Injection, pyridoxine hcl, 100 mg | Office | 2023 | 12 | 85 | $4,250 | $766.68 | 18.0% |
| 82274 | Stool analysis for blood, by fecal hemoglobin determination by immunoassay | Office | 2023 | 49 | 49 | $2,450 | $686.40 | 28.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 52 | 55 | $5,500 | $536.60 | 9.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 14 | 19 | $2,375 | $459.09 | 19.3% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 14 | 15 | $825.00 | $375.45 | 45.5% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2023 | 12 | 528 | $10,560 | $328.52 | 3.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 60 | 87 | $4,350 | $277.17 | 6.4% |
| J3490 | Unclassified drugs | Office | 2023 | 12 | 131 | $30,320 | $255.13 | 0.8% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 24 | 24 | $1,200 | $124.52 | 10.4% |
About Dr. Alex Guevara, D.O
Dr. Alex Guevara, D.O is a Family Medicine healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699768481.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alex Guevara, D.O has received a total of $75,300 in payments from pharmaceutical and medical device companies, with $52,392 received in 2024. These payments were reported across 917 transactions from 65 companies. The most common payment nature is "" ($55,694).
As a Medicare-enrolled provider, Guevara has provided services to 2,876 Medicare beneficiaries, totaling 18,902 services with total Medicare billing of $412,157. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Fort Worth, TX
- Active Since 08/26/2005
- Last Updated 07/08/2010
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1699768481
Products in Payments
- FARXIGA (Drug) $3,828
- Vascepa (Drug) $1,354
- JARDIANCE (Drug) $1,130
- Ozempic (Drug) $877.52
- Kerendia (Drug) $596.61
- Rybelsus (Drug) $464.12
- JANUVIA (Drug) $433.20
- XIFAXAN (Drug) $392.70
- INVOKANA (Drug) $389.61
- TRULICITY (Drug) $353.53
- Korlym (Drug) $341.49
- Ranexa (Drug) $297.49
- MOUNJARO (Drug) $289.35
- TRELEGY ELLIPTA (Drug) $277.95
- Aimovig (Biological) $269.50
- Livalo (Drug) $248.90
- XARELTO (Drug) $237.88
- Xhance (Drug) $236.43
- Repatha (Biological) $234.66
- BREZTRI (Drug) $229.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Fort Worth
Robert Campbell, D.o, D.O
Family Medicine — Payments: $354,620
Family Medicine $354,620
Dr. Michael Carletti, D.o, D.O
Family Medicine — Payments: $48,058
Family Medicine $48,058
Dr. Peter Damico, M.d, M.D
Family Medicine — Payments: $47,108
Family Medicine $47,108
Randall Richwine, Do, DO
Family Medicine — Payments: $32,075
Family Medicine $32,075
Richard Dombroski, Do, DO
Family Medicine — Payments: $25,077
Family Medicine $25,077
Dr. Kenton Murthy, D.o, M.s., M.p.h, D.O, M.S., M.P.H
Family Medicine — Payments: $18,859
Family Medicine $18,859